Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-089241
Filing Date
2024-08-01
Accepted
2024-08-01 16:04:25
Documents
56
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sndx-20240630.htm   iXBRL 10-Q 1885410
2 EX-31.1 sndx-ex31_1.htm EX-31.1 13368
3 EX-31.2 sndx-ex31_2.htm EX-31.2 13898
4 EX-32.1 sndx-ex32_1.htm EX-32.1 12084
  Complete submission text file 0000950170-24-089241.txt   7535746

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sndx-20240630.xsd EX-101.SCH 1026424
59 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20240630_htm.xml XML 1431117
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37708 | Film No.: 241166495
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)